Real‐world outcomes of advanced melanoma patients not represented in phase III trials

The aim was to provide evidence on systemically treated patients with advanced melanoma not represented in phase III trials to support clinical decision‐making. Analysis were performed on advanced melanoma patients diagnosed between 2014 and 2017 in the Netherlands, treated with immune‐ or targeted...

Descripción completa

Detalles Bibliográficos
Autores principales: van Zeijl, Michiel C. T., Ismail, Rawa K., de Wreede, Liesbeth C., van den Eertwegh, Alfonsus J. M., de Boer, Anthonius, van Dartel, Maaike, Hilarius, Doranne L., Aarts, Maureen J. B., van den Berkmortel, Franchette W. P. J., Boers‐Sonderen, Marye J., de Groot, Jan‐Willem B., Hospers, Geke A. P., Kapiteijn, Ellen, Piersma, Djura, van Rijn, Rozemarijn S., Suijkerbuijk, Karijn P. M., ten Tije, Albert J., van der Veldt, Astrid A. M., Vreugdenhil, Gerard, Haanen, John B. A. G., Wouters, Michel W. J. M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2020
Materias:
Cancer Therapy and Prevention
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7689762/
https://www.ncbi.nlm.nih.gov/pubmed/32559817
http://dx.doi.org/10.1002/ijc.33162

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7689762/
https://www.ncbi.nlm.nih.gov/pubmed/32559817
http://dx.doi.org/10.1002/ijc.33162

Ejemplares similares